Your browser doesn't support javascript.
loading
The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance.
Kimura, Izumi; Kosugi, Yusuke; Wu, Jiaqi; Zahradnik, Jiri; Yamasoba, Daichi; Butlertanaka, Erika P; Tanaka, Yuri L; Uriu, Keiya; Liu, Yafei; Morizako, Nanami; Shirakawa, Kotaro; Kazuma, Yasuhiro; Nomura, Ryosuke; Horisawa, Yoshihito; Tokunaga, Kenzo; Ueno, Takamasa; Takaori-Kondo, Akifumi; Schreiber, Gideon; Arase, Hisashi; Motozono, Chihiro; Saito, Akatsuki; Nakagawa, So; Sato, Kei.
Afiliación
  • Kimura I; Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo 1088639, Japan.
  • Kosugi Y; Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo 1088639, Japan; Laboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto Univ
  • Wu J; Department of Molecular Life Science, Tokai University School of Medicine, Isehara, Kanagawa 2591193, Japan; CREST, Japan Science and Technology Agency, Saitama 3220012, Japan.
  • Zahradnik J; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 76100, Israel.
  • Yamasoba D; Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo 1088639, Japan; Faculty of Medicine, Kobe University, Hyogo 6500017, Japan.
  • Butlertanaka EP; Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki 8892192, Japan.
  • Tanaka YL; Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki 8892192, Japan.
  • Uriu K; Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo 1088639, Japan; Graduate School of Medicine, The University of Tokyo, 1130033 Tokyo, Japan.
  • Liu Y; Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Osaka 5650871, Japan; Laboratory of Immunochemistry, World Premier International Immunology Frontier Research Centre, Osaka University, Osaka 5650871, Japan.
  • Morizako N; Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki 8892192, Japan.
  • Shirakawa K; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto 6068507, Japan.
  • Kazuma Y; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto 6068507, Japan.
  • Nomura R; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto 6068507, Japan.
  • Horisawa Y; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto 6068507, Japan.
  • Tokunaga K; Department of Pathology, National Institute of Infectious Diseases, Tokyo 1628640, Japan.
  • Ueno T; Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 8600811, Japan.
  • Takaori-Kondo A; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto 6068507, Japan.
  • Schreiber G; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 76100, Israel.
  • Arase H; Graduate School of Medicine, The University of Tokyo, 1130033 Tokyo, Japan; Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Osaka 5650871, Japan; Center for Infectious Disease Education and Research, Osaka University, Osaka 5650871, Japan.
  • Motozono C; Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 8600811, Japan.
  • Saito A; Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki 8892192, Japan; Center for Animal Disease Control, University of Miyazaki, Miyazaki 8892192, Japan; Graduate School of Medicine and Veterinary Medicine, University of Miyazaki, Miyazaki 8892192, Japan.
  • Nakagawa S; Department of Molecular Life Science, Tokai University School of Medicine, Isehara, Kanagawa 2591193, Japan; CREST, Japan Science and Technology Agency, Saitama 3220012, Japan; Bioinformation and DDBJ Center, National Institute of Genetics, Mishima, Shizuoka 4118540, Japan. Electronic address: so@to
  • Sato K; Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo 1088639, Japan; CREST, Japan Science and Technology Agency, Saitama 3220012, Japan; Graduate School of Medic
Cell Rep ; 38(2): 110218, 2022 01 11.
Article en En | MEDLINE | ID: mdl-34968415
SARS-CoV-2 Lambda, a variant of interest, has spread in some South American countries; however, its virological features and evolutionary traits remain unclear. In this study, we use pseudoviruses and reveal that the spike protein of the Lambda variant is more infectious than that of other variants due to the T76I and L452Q mutations. The RSYLTPGD246-253N mutation, a unique 7-amino acid deletion in the N-terminal domain of the Lambda spike protein, is responsible for evasion from neutralizing antibodies and further augments antibody-mediated enhancement of infection. Although this mutation generates a nascent N-linked glycosylation site, the additional N-linked glycan is dispensable for the virological property conferred by this mutation. Since the Lambda variant has dominantly spread according to the increasing frequency of the isolates harboring the RSYLTPGD246-253N mutation, our data suggest that the RSYLTPGD246-253N mutation is closely associated with the substantial spread of the Lambda variant in South America.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 / Inmunidad Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Rep Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 / Inmunidad Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Rep Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos